MetaRing: Revolutionizing Breast Cancer Therapeutics Through Rapid Plasmonic Biosensing and AI
1. Introduction The treatment of breast cancer remains one of the most complex challenges in modern oncology, primarily due to the high degree of inter-patient and intra-tumor heterogeneity. While chemotherapy remains a cornerstone of treatment, the efficacy of agents like paclitaxel is often hindered by innate or acquired drug resistance. Traditionally, determining a patient’s response to chemotherapy requires weeks of clinical observation or complex laboratory assays. MetaRing: Revolutionizing Breast Cancer Therapeutics Through Rapid Plasmonic Biosensing and AI A research team at the Hefei Institutes of Physical Science (HFIPS), Chinese Academy of Sciences, led by Professor Wang Hongzhi, has introduced a transformative solution: the MetaRing . This programmable plasmonic biosensor, integrated with a lightweight convolutional neural network (CNN), enables the detection of drug sensitivity in breast cancer cells in under 10 minutes with an accuracy exceeding 92%. By leveraging the...